Neurocrine Biosciences, Inc. (NBIX) Reports In-Line Q1 Loss of 1c
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $140.44 +1.47%
EPS Growth %: -12.4%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
OCCI, PMCB, BRID, More
EPS Growth %: -12.4%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
OCCI, PMCB, BRID, More
Join SI Premium – FREE
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q1 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $10.84 million.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler sees Google TPU sales hitting $104BN by 2028
- Barclays Starts Kongsberg Maritime ASA (KMAR:NO) at Overweight
- REA Group to buy 35% stake in Ireland's Distilled for €248m
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
